Core Insights - Aclarion, Inc. is expanding its multi-center CLUE Trial to New Jersey, aiming to assess how often Nociscan's AI data alters initial treatment plans for chronic low back pain patients [1][2] - The trial is expected to attract more spine surgeons, enhancing the data supporting the effectiveness of Nociscan in treatment decision-making [2][4] Company Overview - Aclarion is a healthcare technology company utilizing biomarkers and augmented intelligence algorithms to assist physicians in identifying chronic low back pain sources [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine, leveraging Magnetic Resonance Spectroscopy (MRS) [5] Clinical Significance - Approximately 266 million people globally suffer from degenerative spine disease and low back pain, highlighting the need for effective diagnostic tools [3] - Nociscan quantifies chemical biomarkers associated with disc pain, providing critical insights when combined with other diagnostic methods [3][5] Trial Participation - Dr. Justin Kubeck is the second surgeon to join the CLUE Trial, following Dr. John Keller, with expectations for more surgeons to participate in the coming months [2] - The trial aims to generate real-world evidence to support payer coverage decisions for Nociscan [4]
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey